Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or R
Go back to Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or R| Merck & Co. (NYSE: MRK) | Delayed: 130.42 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $130.42 | 52 Week High | $65.46 | |||
| Open | $130.42 | 52 Week Low | $47.97 | |||
| Day High | $130.42 | P/E | 88.72 | |||
| Day Low | $130.42 | EPS | $1.47 | |||
| Volume | 923,189 | |||||
